State Street Corp Buys 150,323 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

State Street Corp grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 6.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,433,963 shares of the biopharmaceutical company’s stock after purchasing an additional 150,323 shares during the quarter. State Street Corp owned about 2.32% of Revance Therapeutics worth $12,632,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LMR Partners LLP acquired a new stake in shares of Revance Therapeutics during the 3rd quarter worth approximately $11,648,000. Integral Health Asset Management LLC bought a new stake in Revance Therapeutics in the second quarter valued at $1,285,000. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics in the third quarter valued at about $21,605,000. AQR Capital Management LLC raised its stake in shares of Revance Therapeutics by 567.6% in the second quarter. AQR Capital Management LLC now owns 201,080 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 170,960 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Revance Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 790,837 shares of the biopharmaceutical company’s stock worth $4,104,000 after acquiring an additional 41,250 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

Shares of RVNC opened at $3.08 on Thursday. The firm has a market capitalization of $321.52 million, a PE ratio of -1.60 and a beta of 0.82. The stock has a 50 day simple moving average of $4.26 and a 200 day simple moving average of $4.50. Revance Therapeutics, Inc. has a 52-week low of $2.30 and a 52-week high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Equities research analysts predict that Revance Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on RVNC. HC Wainwright restated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. StockNews.com assumed coverage on shares of Revance Therapeutics in a research note on Friday, December 20th. They set a “hold” rating for the company. Barclays dropped their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, Mizuho decreased their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.